With Indian generics entering the race, we may see: Increased global competition More affordable treatments Faster adoption of obesity therapies Conclusion The launch of generic semaglutide by Indian pharmaceutical companies after the March 2026 patent expiry marks a significant step toward affordable diabetes and obesity treatment
Dietary vitamin D intake, 25-hydroxyvitamin D3 levels and premenstrual syndrome in a college-aged population
GLP-1 acts through the GLP-1 receptor (GLP-1R), primarily expressed in the brain, pancreatic islets, and gastrointestinal (GI) tract
While they dont treat Hashimotos itself, they can play a powerful supportive role in improving metabolic health, weight management, and blood sugar regulation for people living with autoimmune thyroid disease
[17] With perfectly portioned single servings that are both tasty and effective, your daily dose couldnt be easier